Institutional investors purchased a net $2.2 million shares of NLNK during the quarter ended June 2016. This may signal that the smart money is gaining interest in this company as the 51.25% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CARNEGIE ASSET MANAGEMENT FONDSM... Sold 13.2 Thousand shares of NewLink Genetics Corp